Fig. 1From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in JapanThe flowchart of phase II clinical trial of sorafenib plus IFN-α for untreated mRCC patients in JapanBack to article page